Organization & Developments: Seres Therapeutics

Parents

*Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome.
2020: SERES THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM SER-109 PHASE 3 ECOSPOR III STUDY IN RECURRENT C. DIFFICILE INFECTION_serestherapeutics
2020: Seres Therapeutics' SER-109 Has Accelerated Growth Potential
2020: Seres: An Interesting Late-Stage Microbiome Development Company
2021: Microbiome therapy companies face the fallout of failed Seres trial
2022: Seres Gets Closer To Good Times_ seekingalpha.com
2022: Seres Therapeutics (MCRB) Investor Presentation - Slideshow_ seekingalpha.com
2022: Seres Therapeutics Is Playing A Long Game_seekingalpha.com
2023: Seres Gets FDA Approval And The Share Price Goes Down!_ seekingalpha.com
2023: Seres Therapeutics: Evaluating Vowst's Market Challenges (Rating Downgrade)
2023: With first microbiome drug approved, Seres slims R&D efforts and workforce 41%
2024: Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
2024: Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns
2024: Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade
2025: Seres shrinks head count by 25% to fund phase 2 study of infection biotherapeutic